Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
22 February 2024 - 12:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will
provide business updates and report its financial results for the
fourth quarter and full year ended December 31, 2023 on Wednesday,
February 28, 2024. The company will host a conference call and
webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 877-270-2148
(domestic) or 412-902-6510 (international). A live webcast of the
presentation will be available on the Investors & Media section
of the Mersana website at www.mersana.com, and a replay of the
webcast will be available in the same location following the
conference call for approximately 90 days.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel antibody-drug conjugates (ADCs) and driven by
the knowledge that patients are waiting for new treatment options.
The company has developed proprietary cytotoxic (Dolasynthen) and
immunostimulatory (Immunosynthen) ADC platforms that are generating
a pipeline of wholly-owned and partnered product candidates with
the potential to treat a range of cancers. Its pipeline includes
XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an
Immunosynthen ADC targeting a novel epitope of human epidermal
growth factor receptor 2 (HER2). Mersana routinely posts
information that may be useful to investors on the “Investors &
Media” section of its website at www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2024 to May 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From May 2023 to May 2024